Abstract 221P
Background
First-line immune checkpoint inhibitor (ICI) for cisplatin-ineligible metastatic urothelial carcinoma patients has been approved by FDA and EMA. However, there is still a lack of evidence to directly compare treatment efficacy between ICI and conventional carboplatin-based chemotherapy. Here we conduct a retrospective analysis to compare the survival outcome between ICI and carboplatin treatment.
Methods
The study enrolled 130 metastatic urothelial carcinoma patients who underwent first-line ICI or carboplatin-based chemotherapy at Kaohsiung and Linko Chang Gung Memorial Hospital between May 2001 and Jun 2019. Kaplan-Meier analyses and Cox proportional regression models were used for univariate and multivariate survival analyses.
Results
In total, there were 44 patients (34%) in the ICI group and 86 patients (66%) in the carboplatin group. The median OS was insignificantly different between ICI and carboplatin groups, accounting for 11.1 and 9.5 months (p = 0.46), respectively. The median PFS in ICI and carboplatin groups were 2.5 and 3.7 months, respectively (p = 0.92). On subgroup analysis, OS was significantly worse for ICI treatment in patients with elevated pretreatment white blood cell count (WBC ≥ 10000 × 103/μL) compared with those on carboplatin group (HR 2.41, 95% CI 1.1 – 5.25, p = 0.03).
Conclusions
In this real-world data analysis, we didn’t show significant survival difference in first-line treatment with ICI and carboplatin-based chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract